Latest Ratios: P/E Ratio 14.0x · EV/EBITDA 6.6x · ROE -14.2%. (2000–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.5B | $607M | $913M | $2.9B | $4.6B | $5.9B | $3.3B | $3.0B | $2.8B | $2.4B | $1.9B |
| Enterprise Value | $2.2B | $1.4B | $2.0B | $4.3B | $5.4B | $6.6B | $4.2B | $3.6B | $3.2B | $2.7B | $2.2B |
| P/E Ratio → | 14.04 | — | — | 13.97 | 10.39 | 17.96 | 46.11 | 25.96 | 19.47 | 18.38 | 17.88 |
| P/S Ratio | 0.42 | 0.22 | 0.31 | 0.78 | 0.88 | 1.48 | 1.36 | 1.33 | 1.29 | 1.22 | 1.00 |
| P/B Ratio | 2.29 | 0.95 | 1.29 | 3.54 | 4.42 | 5.06 | 3.97 | 4.03 | 4.32 | 4.33 | 4.22 |
| P/FCF | 4.52 | 2.60 | 3.81 | 10.97 | 8.05 | 23.35 | 14.95 | 15.74 | 14.47 | 27.44 | 17.24 |
| P/OCF | 5.48 | 2.25 | 2.85 | 7.92 | 7.06 | 19.25 | 12.67 | 13.19 | 12.15 | 21.12 | 14.37 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.50 | 0.67 | 1.13 | 1.03 | 1.65 | 1.75 | 1.62 | 1.49 | 1.38 | 1.18 |
| EV / EBITDA | 6.58 | 7.25 | 28.14 | 8.54 | 6.90 | 11.28 | 17.17 | 15.31 | 13.05 | 11.19 | 10.15 |
| EV / EBIT | 67.75 | — | — | 12.60 | 8.36 | 13.73 | 28.01 | 20.38 | 15.70 | 12.89 | 11.72 |
| EV / FCF | — | 5.89 | 8.35 | 15.88 | 9.44 | 26.08 | 19.20 | 19.13 | 16.71 | 30.87 | 20.44 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 28.3% | 28.3% | 30.8% | 33.0% | 32.7% | 32.9% | 33.1% | 33.5% | 32.6% | 32.4% | 32.6% |
| Operating Margin | 1.2% | 1.2% | -3.4% | 8.9% | 12.3% | 12.0% | 6.2% | 8.0% | 9.5% | 10.7% | 10.1% |
| Net Profit Margin | -3.5% | -3.5% | -4.9% | 5.6% | 8.5% | 8.2% | 3.0% | 5.1% | 6.6% | 6.7% | 5.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -14.2% | -14.2% | -19.1% | 22.5% | 40.3% | 33.0% | 9.1% | 16.6% | 23.6% | 26.2% | 26.6% |
| ROA | -4.2% | -4.2% | -5.5% | 7.2% | 14.8% | 11.9% | 3.3% | 6.7% | 10.3% | 10.9% | 10.2% |
| ROIC | 1.6% | 1.6% | -3.9% | 12.7% | 26.3% | 19.9% | 7.2% | 10.9% | 15.7% | 19.1% | 21.2% |
| ROCE | 2.0% | 2.0% | -5.0% | 15.7% | 30.9% | 23.4% | 8.6% | 12.9% | 18.7% | 22.4% | 24.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.25 | 1.25 | 1.55 | 1.62 | 0.82 | 0.75 | 1.17 | 0.98 | 0.69 | 0.57 | 0.81 |
| Debt / EBITDA | 4.23 | 4.23 | 15.44 | 2.70 | 1.10 | 1.49 | 3.92 | 3.07 | 1.81 | 1.31 | 1.64 |
| Net Debt / Equity | — | 1.20 | 1.54 | 1.58 | 0.76 | 0.59 | 1.13 | 0.87 | 0.67 | 0.54 | 0.78 |
| Net Debt / EBITDA | 4.05 | 4.05 | 15.29 | 2.64 | 1.02 | 1.18 | 3.80 | 2.72 | 1.75 | 1.25 | 1.59 |
| Debt / FCF | — | 3.29 | 4.54 | 4.91 | 1.39 | 2.73 | 4.25 | 3.39 | 2.24 | 3.43 | 3.21 |
| Interest Coverage | -1.22 | -1.22 | -1.47 | 6.25 | 16.02 | 14.03 | 2.59 | 6.22 | 12.56 | 10.80 | 12.39 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.94 | 0.94 | 1.09 | 1.28 | 1.27 | 1.39 | 1.26 | 1.48 | 1.57 | 1.79 | 1.64 |
| Quick Ratio | 0.94 | 0.94 | 1.09 | 1.28 | 1.27 | 1.39 | 1.17 | 1.48 | 1.44 | 1.57 | 1.51 |
| Cash Ratio | 0.06 | 0.06 | 0.02 | 0.05 | 0.08 | 0.19 | 0.07 | 0.22 | 0.05 | 0.06 | 0.04 |
| Asset Turnover | — | 1.30 | 1.24 | 1.30 | 1.82 | 1.27 | 1.02 | 1.15 | 1.43 | 1.59 | 1.60 |
| Inventory Turnover | — | — | — | — | — | — | 41.24 | — | 36.41 | 23.21 | 37.22 |
| Days Sales Outstanding | — | 58.70 | 63.61 | 71.91 | 66.36 | 94.25 | 68.63 | 70.86 | 71.22 | 74.78 | 75.13 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 7.1% | — | — | 7.2% | 9.6% | 5.6% | 2.2% | 3.9% | 5.1% | 5.4% | 5.6% |
| FCF Yield | 22.1% | 38.5% | 26.2% | 9.1% | 12.4% | 4.3% | 6.7% | 6.4% | 6.9% | 3.6% | 5.8% |
| Buyback Yield | 0.1% | 0.3% | 0.0% | 14.4% | 12.5% | 0.0% | 0.2% | 0.6% | 2.4% | 0.8% | 0.7% |
| Total Shareholder Yield | 0.1% | 0.3% | 0.0% | 14.4% | 12.5% | 0.0% | 0.2% | 0.6% | 2.4% | 0.8% | 0.7% |
| Shares Outstanding | — | $39M | $38M | $39M | $45M | $48M | $48M | $48M | $49M | $49M | $49M |
Includes 30+ ratios · 26 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AMN stock.
AMN Healthcare Services, Inc.'s current P/E ratio is 14.0x. The historical average is 35.9x. This places it at the 11th percentile of its historical range.
AMN Healthcare Services, Inc.'s current EV/EBITDA is 6.6x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 17.7x.
AMN Healthcare Services, Inc.'s return on equity (ROE) is -14.2%. The historical average is 8.6%.
Based on historical data, AMN Healthcare Services, Inc. is trading at a P/E of 14.0x. This is at the 11th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
AMN Healthcare Services, Inc. has 28.3% gross margin and 1.2% operating margin.
AMN Healthcare Services, Inc.'s Debt/EBITDA ratio is 4.2x, indicating high leverage. A ratio above 4x may signal elevated financial risk.
Key Metrics
Top Statement Risk
Hospital labor demand volatility
Metrics are mathematically derived from official filings.
Low Multiples Price in Cyclical Risk
Based on reported figures, AMN trades at 13.33x trailing P/E and 6.36x EV/EBITDA, a discount to CHE's 16.17x EV/EBITDA and HCSG's 11.88x, suggesting the market prices AMN as a cyclical staffing business rather than a healthcare technology platform.
The forward P/E of 11.01 implies modest expected earnings growth, yet this must be weighed against trailing negative net margin of -3.50% and negative ROE of -14.2%, which make the trailing P/E less meaningful as a clean earnings anchor. The P/FCF of 4.29 looks inexpensive, but it is distorted by the negative free cash flow in recent quarters and should be read as a function of working capital timing rather than durable cash generation. Investors should monitor whether the valuation discount narrows if the Technology and Workforce segment grows as a share of revenue.
Margin Recovery Masked by Overhead Drag
As reported in financial statements, AMN's gross margin rose to 31.9% in 2026Q3 from 26.1% in 2025Q4, yet operating margin of 7.0% and trailing net margin of -3.5% indicate that SG&A absorbs most of the gross profit improvement.
The gap between a 28.35% gross margin and a 1.21% operating margin implies a high fixed overhead burden relative to a variable-cost clinician model, which limits operating leverage on incremental revenue. Quarterly net margin of 4.7% in 2026Q3 contrasts sharply with the trailing negative figure, suggesting earnings remain volatile and sensitive to impairment or one-time items. Investors should treat the recent quarter as evidence of recovery to be confirmed by sustained operating margin expansion.
Deleveraging Improves Coverage Profile
According to recent quarterly figures, AMN's debt-to-equity fell from 1.57 in 2025Q2 to 0.96 in 2026Q3 while interest coverage recovered to 6.89x, indicating debt service has become considerably more comfortable than during the prior trough.
The reduction in debt from roughly $956M to $743M appears to have driven most of the leverage improvement, rather than equity expansion alone. Debt-to-EBITDA of 9.03x remains elevated relative to typical staffing peers, so the coverage improvement depends heavily on continued EBITDA recovery. Refinancing exposure and the sensitivity of earnings to a renewed demand downturn warrant further investigation.
Cash Rebuild Offsets Thin Current Cushion
Based on reported figures, AMN's cash rose to $256.0M in 2026Q3 from $34.0M at 2025Q4, lifting the current ratio to 1.21, a buffer that was previously very limited and remains modest relative to total liabilities.
The current ratio equal to the quick ratio at 1.21 indicates that inventory is not a meaningful component of liquidity for this service-based model, so liquidity rests almost entirely on cash and receivables. Receivables-dependent liquidity is exposed if hospital customers delay payments under budget pressure, a risk reflected in the DSO of 54 days. Under a severe stress scenario, the position would depend on sustained collections, and the recent history of sharp working capital swings suggests this cushion may be less durable than the headline ratio implies.
Misapplied P/E Obscures Acquisition Amortization
Based on reported figures, the trailing P/E of 13.33x is most commonly misapplied to AMN, because heavy acquisition-related amortization and impairment charges distort GAAP earnings and make the multiple look cheaper or more expensive than the underlying business warrants.
Investors often use GAAP P/E as a shorthand for earning power, but AMN's earnings are depressed by amortization from acquisitions such as B.E. Smith and Stratus, which creates a wide gap between GAAP and adjusted results. A more informative approach would be EV/EBITDA adjusted for stock-based compensation, combined with free cash flow yield normalized for working capital timing. Investors should monitor whether the gap between GAAP and adjusted earnings narrows as acquisition intangibles amortize.